- Home
- PFD vs ANTX Comparison
PFD vs ANTX Comparison
Compare PFD & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFD | ANTX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 170.6M |
| IPO Year | 1996 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PFD | ANTX |
|---|---|---|
| Price | $11.48 | $3.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 24.7K | ★ 215.7K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.98 | $1.00 |
| 52 Week High | $12.16 | $6.91 |
Technical Indicators
Market Signals| Indicator | PFD | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.12 | 38.80 |
| Support Level | $11.31 | $1.06 |
| Resistance Level | $11.56 | $5.13 |
| Average True Range (ATR) | 0.09 | 0.39 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 64.58 | 8.08 |
Price Performance
Historical ComparisonAbout PFD Flaherty & Crumrine Preferred and Income Fund Incorporated
Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.